Compare Biogen Inc (BIIB) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Tyson Foods, Inc. — how do they compare? Biogen Inc trades at $190.32 (market cap $28.34B), while Tyson Foods, Inc. trades at $57.62 (market cap $20.24B). The key difference: Biogen Inc is the larger of the two by market cap, and Tyson Foods, Inc. pays a 3.55% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | TSN | |
|---|---|---|
Market Cap | $28.34B | $20.24B |
Sector | Health | Consumer Staples |
52-Week High | $216.63 | $68.75 |
52-Week Low | $122.68 | $50.72 |
Enterprise Value | $30.62B | $27.82B |
Dividend Yield | — | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Tyson Foods (TSN) trades at $57.92, up 0.16% on the day, with a bearish technical signal but mixed earnings performance including a Q1 2026 beat. The company shows modest revenue growth to $54.44 billion in 2025, though net margins are thin at 0.81%. Recent news highlights innovation in prepared foods and new leadership appointments, while analyst consensus leans bullish with a $68.80 price target.
The stock presents a value opportunity with low P/S and P/B ratios, but faces risks from volatile earnings, high debt, and competitive pressures. Upside depends on execution in value-added segments and cost management, with the current price offering a 19% discount to the consensus target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
